Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres.

ABSTRACT:

Introduction

Bevacizumab, a vascular endothelial growth factor inhibitor, is used off-label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right-sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).

Aim

To report the experience of treatment with bevacizumab within European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN) centres.

Method

A retrospective analysis of the usage, availability, efficacy and safety in HHT patients treated with bevacizumab in European VASCERN centres.

Results

A total of 151 patients received treatment with bevacizumab in European VASCERN centres. Most patients were treated in Denmark, France a

SUBMITTER: Haahr PD 

PROVIDER: S-EPMC12850601 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature